A growing movement is exploring the concept of human enhancement, aiming to optimize and upgrade the human body through various technologies. This includes life extension, brain implants, and drugs designed to enhance cognitive and physical capabilities. The Economist has highlighted this trend, noting its shift from fringe ideas to mainstream discussion. One notable development in this field is the work of NewLimit, a San Francisco-based startup focused on epigenetic reprogramming. The company, co-founded by Coinbase CEO Brian Armstrong and having secured a $40 million Series A financing, has made progress in restoring 'youthful function' to liver and immune cells. Researchers at NewLimit have identified new transcription factor sets that could potentially treat liver disease and immune dysfunction, specifically targeting hepatocytes and T cells, including CD8 T cells. The human enhancement industry is already valued at $125 billion and growing by more than 10% annually, according to one estimate. This growth is driven by both enthusiastic investors and governmental encouragement, suggesting a future where treatments, such as LNP-mRNA medicine tested in an ethanol injury mouse model, could redefine human capabilities.